The Cognify Trial

Alberto Rivera, MD, FAAPMR, currently serves as principal investigator of the Cognify Trial, in which he administers the monoclonal antibody TB-006 to patients living with Alzheimer's disease. The trial represents a direct extension of the clinical conviction that has animated his career: that neuroinflammation and the oxidative cascades driving neurodegeneration belong to the same upstream biology he identified as the Oxygen Free Radical Crisis.

The GENEFLAMMATION framework, which maps polygenic vulnerability across antioxidant, methylation, detoxification, and inflammatory regulatory pathways, finds direct application in neurodegenerative disease. Alzheimer's is not a disease of memory loss. It is a disease of neuroinflammatory dysregulation, mitochondrial dysfunction, and oxidative neurodegeneration — a tissue-specific expression of the same systemic biology Dr. Rivera has spent his career characterizing.

TB-006 is a monoclonal antibody designed to intervene at the immunological level of this cascade. Dr. Rivera's role as principal investigator places him at the interface between precision immunology and the genomic framework he built, and reflects his conviction that precision immunological intervention at the upstream biological level offers a path forward that symptomatic pharmacological approaches cannot provide.

The Cognify Trial is a demonstration, in the most rigorous clinical context available, that the biology Dr. Rivera has been describing — the Oxygen Free Radical Crisis as the universal driver of chronic disease — extends to the brain, and that the tools of precision medicine are adequate to the task of intervening there.